Literature DB >> 25716342

Are all cases of paediatric essential thrombocythaemia really myeloproliferative neoplasms? Analysis of a large cohort.

Maria L Randi1, Giulia Geranio, Irene Bertozzi, Concetta Micalizzi, Ugo Ramenghi, Fabio Tucci, Lucia D Notarangelo, Saverio Ladogana, Giuseppe Menna, Paola Giordano, Caterina Consarino, Piero Farruggia, Giulio A Zanazzo, Giovanni M Fiori, Roberta Burnelli, Giovanna Russo, Momcilo Jankovich, Edoardo Peroni, Elena Duner, Giuseppe Basso, Fabrizio Fabris, Maria C Putti.   

Abstract

Sporadic essential thrombocythaemia (ET) is rare in paediatrics, and the diagnostic and clinical approach to paediatric cases cannot be simply copied from experience with adults. Here, we assessed 89 children with a clinical diagnosis of ET and found that 23 patients (25·8%) had a clonal disease. The JAK2 V617F mutation was identified in 14 children, 1 child had the MPL W515L mutation, and 6 had CALR mutations. The monoclonal X-chromosome inactivation pattern was seen in six patients (two with JAK2 V617F and two with CALR mutations). The other 66 patients (74·2%) had persistent thrombocytosis with no clonality. There were no clinical or haematological differences between the clonal and non-clonal patients. The relative proportion of ET-specific mutations in the clonal children was much the same as in adults. The higher prevalence of non-clonal cases suggests that some patients may not have myeloproliferative neoplasms, with significant implications for their treatment.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  CALR; JAK2; essential thrombocythaemia; myeloproliferative neoplasm; paediatric

Mesh:

Substances:

Year:  2015        PMID: 25716342     DOI: 10.1111/bjh.13329

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Mutational profile of childhood myeloproliferative neoplasms.

Authors:  A Karow; R Nienhold; P Lundberg; E Peroni; M C Putti; M L Randi; R C Skoda
Journal:  Leukemia       Date:  2015-07-30       Impact factor: 11.528

2.  Chasing down the triple-negative myeloproliferative neoplasms: Implications for molecular diagnostics.

Authors:  Stephen E Langabeer
Journal:  JAKSTAT       Date:  2016-11-14

3.  Thrombopoietin Measurement as a Key Component in the Evaluation of Pediatric Thrombocytosis.

Authors:  Nya D Nelson; Andrea Marcogliese; Katie Bergstrom; Michael Scheurer; Donald Mahoney; Alison A Bertuch
Journal:  Pediatr Blood Cancer       Date:  2016-04-21       Impact factor: 3.167

4.  Essential Thrombocythemia in a Two-year-old Child, Responsive to Hydroxyurea but Not Aspirin.

Authors:  Tariq N Aladily; Randa S Mohammad; Ali Al-Khader; Abdalla S Awidi
Journal:  Oman Med J       Date:  2017-05

Review 5.  Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management.

Authors:  Clemens Stockklausner; C M Duffert; H Cario; R Knöfler; W Streif; A E Kulozik
Journal:  Ann Hematol       Date:  2021-03-12       Impact factor: 3.673

6.  Distinct molecular abnormalities underlie unique clinical features of essential thrombocythemia in children.

Authors:  R Fu; D Liu; Z Cao; S Zhu; H Li; H Su; L Zhang; F Xue; X Liu; X Zhang; T Cheng; R Yang; L Zhang
Journal:  Leukemia       Date:  2015-06-29       Impact factor: 11.528

7.  Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review.

Authors:  Jean-Christophe Ianotto; Natalia Curto-Garcia; Marie Lauermanova; Deepti Radia; Jean-Jacques Kiladjian; Claire N Harrison
Journal:  Haematologica       Date:  2019-01-24       Impact factor: 9.941

Review 8.  Essential Thrombocythemia in Children and Adolescents.

Authors:  Maria Caterina Putti; Irene Bertozzi; Maria Luigia Randi
Journal:  Cancers (Basel)       Date:  2021-12-06       Impact factor: 6.639

Review 9.  Human growth disorders associated with impaired GH action: Defects in STAT5B and JAK2.

Authors:  Vivian Hwa
Journal:  Mol Cell Endocrinol       Date:  2020-10-27       Impact factor: 4.102

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.